ScholarLens Back to search
2019•BioanalysisRequires access

LC–MS/MS Method for Simultaneous Determination of Rivaroxaban and Metformin in Rat Plasma: Application to Pharmacokinetic Interaction Study

Shouchang Gai, Anli Huang, Feng Tian, Nan Gou, Xingchen Tony Wang, Chunling Lu, Hongyun Tang, XU Dapeng, Binbin Zhang, Libin Wang

Open publisher page 13 citations

Abstract

Aim: A reliable, sensitive and simple LC–MS/MS method has been established and validated for the quantitation of rivaroxaban (RIV) and metformin (MET) in rat plasma. Results: The procedure of method validation was conducted according to the guiding principles of EMA and US FDA. At the same time, the method was applied to pharmacokinetic interactions study between RIV and MET for the first time. When RIV and MET coadministered to rats, pharmacokinetic parameters of MET like AUC(0-t), AUC(0-∞) and Cmax had statistically significant increased. tmax of RIV was prolonged without affecting t1/2 obviously and Cmax was inhibited significantly (p < 0.05) by comparison to the single group. Conclusion: The results indicated that drug–drug interactions occurred when the coadministration of RIV and MET.

About this research paper

What this paper is about

Aim: A reliable, sensitive and simple LC–MS/MS method has been established and validated for the quantitation of rivaroxaban (RIV) and metformin (MET) in rat plasma. Results: The procedure of method validation was conducted according to the guiding principles of EMA and US FDA. At the same time, the method was applied to pharmacokinetic interactions study between RIV and MET for the first time. When RIV and MET coadministered to rats, pharmacokinetic parameters of MET like AUC(0-t), AUC(0-∞) and Cmax had statistically significant increased. tmax of RIV was prolonged without affecting t1/2 obviously and Cmax was inhibited significantly (p < 0.05) by comparison to the single group. Conclusion: The results indicated that drug–drug interactions occurred when the coadministration of RIV and MET.

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Aim: A reliable, sensitive and simple LC–MS/MS method has been established and validated for the quantitation of rivaroxaban (RIV) and metformin (MET) in rat plasma. Results: The procedure of method validation was conducted according to the guiding principles of EMA and US FDA. At the same time, the method was applied to pharmacokinetic interactions study between RIV and MET for the first time. When RIV and MET coadministered to rats, pharmacokinetic parameters of MET like AUC(0-t), AUC(0-∞) and Cmax had statistically significant increased. tmax of RIV was prolonged without affecting t1/2 obviously and Cmax was inhibited significantly (p < 0.05) by comparison to the single group. Conclusion: The results indicated that drug–drug interactions occurred when the coadministration of RIV and MET.

Key concepts: Pharmacokinetics, Metformin, Pharmacology, Plasma concentration, Rivaroxaban, Chemistry, Drug, Chromatography

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
LC–MS/MS Method for Simultaneous Determination of Rivaroxaban and Metformin in Rat Plasma: Application to Pharmacokinetic Interaction Study — Research Paper | ScholarLens